{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:23:49Z","timestamp":1765808629190,"version":"3.48.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.7759\/cureus.99280","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:20:00Z","timestamp":1765808400000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Dupilumab Monotherapy in Pemphigoid Nodularis and a Comprehensive Literature Review"],"prefix":"10.7759","author":[{"given":"Salman M","family":"Albthali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falah M","family":"Alajmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saood","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humoud","family":"Al-sabah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"A case of bullous pemphigoid with nodular lesions","volume":"46","author":"Yashimoto T","year":"1984","unstructured":"Yashimoto T, Otsuka F, Takayama H, Manabe M, Koyama K, Kotake H, Tomii K. A case of bullous pemphigoid with nodular lesions. Nishinihon J Dermatol. 1984, 46:918-22.","journal-title":"Nishinihon J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.7057","article-title":"Pemphigoid nodularis-rare presentation of bullous pemphigoid: a case report and literature review","volume":"17","author":"Vornicescu C","year":"2019","unstructured":"Vornicescu C, \u0218enil\u0103 SC, Cosgarea R, Candrea E, Pop AD, Ungureanu L. Pemphigoid nodularis-rare presentation of bullous pemphigoid: a case report and literature review. Exp Ther Med. 2019, 17:1132-8. 10.3892\/etm.2018.7057","journal-title":"Exp Ther Med"},{"key":"ref3","article-title":"Omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review","volume":"13","author":"Granados-Betancort E","year":"2014","unstructured":"Granados-Betancort E, S\u00e1nchez-D\u00edaz M, Mu\u00f1oz-Barba D, Arias-Santiago S. Omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review. J Clin Med. 2014, 13:4844.","journal-title":"J Clin Med"},{"key":"ref4","article-title":"Dupilumab for prurigo nodularis: case series and review of the literature","volume":"33","author":"Holm JG","year":"2020","unstructured":"Holm JG, Agner T, Sand C, Thomsen SF. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol Ther. 2020, 33:e13222.","journal-title":"Dermatol Ther"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich H","year":"2023","unstructured":"Olbrich H, Sadik CD, Ludwig RJ, Thaci D, Boch K. Dupilumab in inflammatory skin diseases: a systematic review. Biomolecules. 2023, 13:634.","journal-title":"Biomolecules"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdcr.2023.09.018","article-title":"Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus","volume":"42","author":"Jiang C","year":"2023","unstructured":"Jiang C, Adjei S, Santiago S, Lu J, Duran M, Tyring S. Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus. JAAD Case Reports. 2023, 42:12-5.","journal-title":"JAAD Case Reports"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-022-00719-7","article-title":"Management of coexisting bullous pemphigoid and psoriasis: a review","volume":"23","author":"Hsieh CY","year":"2022","unstructured":"Hsieh CY, Tsai TF. Management of coexisting bullous pemphigoid and psoriasis: a review. Am J Clin Dermatol. 2022, 23:869-79.","journal-title":"Am J Clin Dermatol"},{"key":"ref8","article-title":"Advancing treatment in bullous pemphigoid: a comprehensive review of novel therapeutic targets and approaches","volume":"65","author":"Chen HC","year":"2023","unstructured":"Chen HC, Wang CW, Toh WH, Lee HE, Chung WH, Chen CB. Advancing treatment in bullous pemphigoid: a comprehensive review of novel therapeutic targets and approaches. Clin Rev Allergy Immunol. 2023, 65:331-53.","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref9","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell DF","year":"2024","unstructured":"Murrell DF, Joly P, Werth VP, et al.. Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT. Adv Ther. 2024, 41:2991-3002.","journal-title":"Adv Ther"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1177\/12034754251351854","article-title":"Navigating bullous pemphigoid: consensus recommendations for diagnosis and management-a Canadian perspective","volume":"29","author":"Lovegrove FE","year":"2025","unstructured":"Lovegrove FE, Sauder MB, Mufti A, et al.. Navigating bullous pemphigoid: consensus recommendations for diagnosis and management-a Canadian perspective. J Cutan Med Surg. 2025, 29:661-74.","journal-title":"J Cutan Med Surg"},{"key":"ref11","article-title":"Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study","volume":"14","author":"Wang SH","year":"2023","unstructured":"Wang SH, Shan Y, Li SZ, Zuo YG. Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study. Front Immunol. 2023, 14:1165106.","journal-title":"Front Immunol"},{"key":"ref12","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad H","year":"2025","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, et al.. Bullous pemphigoid. Nat Rev Dis Primers. 2025, 11:12.","journal-title":"Nat Rev Dis Primers"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-024-02992-w","article-title":"Pathophysiology of bullous pemphigoid: role of type 2 inflammation and emerging treatment strategies (narrative review)","volume":"41","author":"Werth VP","year":"2024","unstructured":"Werth VP, Murrell DF, Joly P, Heck R, Orengo JM, Ardeleanu M, Hultsch V. Pathophysiology of bullous pemphigoid: role of type 2 inflammation and emerging treatment strategies (narrative review). Adv Ther. 2024, 41:4418-32.","journal-title":"Adv Ther"},{"key":"ref14","article-title":"Taiwanese Dermatological Association consensus for the diagnosis and management of prurigo nodularis","volume":"43","author":"Lan CC","year":"2025","unstructured":"Lan CC, Chung WH, Chen YY, et al.. Taiwanese Dermatological Association consensus for the diagnosis and management of prurigo nodularis. Dermatologica Sinica. 2025, 43:2-13.","journal-title":"Dermatologica Sinica"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly P","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, et al.. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002, 346:321-7. 10.1056\/NEJMoa011592","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly P","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017, 389:2031-40. 10.1016\/S0140-6736(17)30070-3","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye A","year":"2018","unstructured":"Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018, 154:1225-6. 10.1001\/jamadermatol.2018.2526","journal-title":"JAMA Dermatol"},{"key":"ref18","article-title":"Dupilumab for the treatment of prurigo nodularis: a systematic review","volume":"14","author":"Cao P","year":"2023","unstructured":"Cao P, Xu W, Jiang S, Zhang L. Dupilumab for the treatment of prurigo nodularis: a systematic review. Front Immunol. 2023, 14:1092685.","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57101061","article-title":"Bullous pemphigoid and other pemphigoid dermatoses","volume":"57","author":"Pratasava V","year":"2021","unstructured":"Pratasava V, Sahni VN, Suresh A, Huang S, Are A, Hsu S, Motaparthi K. Bullous pemphigoid and other pemphigoid dermatoses. Medicina. 2021,  57:1061.","journal-title":"Medicina"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2025.04.012","article-title":"Patient outcomes and safety of combination biologic therapy with dupilumab: a systematic review","volume":"135","author":"Keow S","year":"2025","unstructured":"Keow S, Lu B, Xiong G, Yu E, Weng D, Abu-Hilal M. Patient outcomes and safety of combination biologic therapy with dupilumab: a systematic review. Ann Allergy Asthma Immunol. 2025, 135:23-30.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdcr.2024.09.030","article-title":"Effective treatment of recalcitrant Hailey-Hailey disease with dupilumab","volume":"55","author":"Patel D","year":"2025","unstructured":"Patel D, Rosenberg J, Cohen J, Holland KE. Effective treatment of recalcitrant Hailey-Hailey disease with dupilumab. JAAD Case Reports. 2025, 55:105-10.","journal-title":"JAAD Case Reports"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"26","author":"Schmidt E","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013, 26:320-32. 10.1016\/S0140-6736(12)61140-4","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.07.013","article-title":"Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab","volume":"6","author":"F\u00e4ssler M","year":"2020","unstructured":"F\u00e4ssler M, Schlapbach C. Granuloma annulare arising under systemic psoriasis therapy successfully treated with adalimumab. JAAD Case Rep. 2020, 6:832-4. 10.1016\/j.jdcr.2020.07.013","journal-title":"JAAD Case Rep"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010328","article-title":"The intriguing links between psoriasis and bullous pemphigoid","volume":"12","author":"Maronese CA","year":"2022","unstructured":"Maronese CA, Cassano N, Genovese G, Foti C, Vena GA, Marzano AV. The intriguing links between psoriasis and bullous pemphigoid. J Clin Med. 2022, 12:328.","journal-title":"J Clin Med"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050373","article-title":"Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics","volume":"13","author":"Zhang J","year":"2023","unstructured":"Zhang J, Wang SH, Zuo YG. Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics. Frontiers in Immunology. 2023, 13:1050373.","journal-title":"Frontiers in Immunology"},{"key":"ref26","article-title":"Fast itch relief during dupilumab predicts clinical efficacy in bullous pemphigoid: a retrospective cohort study","volume":"240","author":"Thevan J","year":"2024","unstructured":"Thevan J, Schmauch E, Nilsson J, et al.. Fast itch relief during dupilumab predicts clinical efficacy in bullous pemphigoid: a retrospective cohort study. Dermatology. 2024, 240:694-701.","journal-title":"Dermatology"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.2174\/0115748871263396231121060901","article-title":"Potential indications of dupilumab in Th-2 inflammatory disease","volume":"19","author":"Ilaria P","year":"2024","unstructured":"Ilaria P, Nevena S, Ersilia T, et al.. Potential indications of dupilumab in Th-2 inflammatory disease. Rev Recent Clin Trials. 2024, 19:53-61.","journal-title":"Rev Recent Clin Trials"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430498-a-rare-case-of-dupilumab-monotherapy-in-pemphigoid-nodularis-and-a-comprehensive-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:20:03Z","timestamp":1765808403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430498-a-rare-case-of-dupilumab-monotherapy-in-pemphigoid-nodularis-and-a-comprehensive-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.99280","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}